Compare HIPO & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIPO | DRTS |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | Israel |
| Employees | 540 | 121 |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 676.8M | 609.0M |
| IPO Year | N/A | N/A |
| Metric | HIPO | DRTS |
|---|---|---|
| Price | $27.26 | $7.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $38.67 | $8.67 |
| AVG Volume (30 Days) | 84.6K | ★ 212.4K |
| Earning Date | 04-30-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.32 | N/A |
| Revenue Next Year | $23.24 | $965.57 |
| P/E Ratio | $7.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.92 | $2.50 |
| 52 Week High | $38.98 | $8.60 |
| Indicator | HIPO | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 62.53 |
| Support Level | $27.00 | $6.37 |
| Resistance Level | $31.92 | $8.60 |
| Average True Range (ATR) | 0.82 | 0.43 |
| MACD | 0.24 | 0.09 |
| Stochastic Oscillator | 97.65 | 90.76 |
Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.